WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

StimCardio raises $30M to run a wrist-worn nerve stimulator alongside AF ablation FDA early alert covers every Medline brand bed after two deaths CereVasc wins an IDE to test its endovascular CSF shunt in early Alzheimer's Boston Scientific puts the August cyberattack at $150M of lost third quarter sales Boston Scientific pushes its $14.5B Penumbra close into early 2027 GT Metabolic raises a Series C from J.P. Morgan for magnetic anastomosis Ottobock leads a $10.5M Series A in prosthetic control startup Blue Arbor Abbott wins the first US approval for a transcatheter paravalvular leak device Pharaoh Neuro takes a Breakthrough designation for filtering blood out of spinal fluid StimCardio raises $30M to run a wrist-worn nerve stimulator alongside AF ablation FDA early alert covers every Medline brand bed after two deaths CereVasc wins an IDE to test its endovascular CSF shunt in early Alzheimer's Boston Scientific puts the August cyberattack at $150M of lost third quarter sales Boston Scientific pushes its $14.5B Penumbra close into early 2027 GT Metabolic raises a Series C from J.P. Morgan for magnetic anastomosis Ottobock leads a $10.5M Series A in prosthetic control startup Blue Arbor Abbott wins the first US approval for a transcatheter paravalvular leak device Pharaoh Neuro takes a Breakthrough designation for filtering blood out of spinal fluid

Series A

Ottobock leads a $10.5M Series A in prosthetic control startup Blue Arbor

MedDevice Startups Staff · 2 days ago · 2 min read · Via Blue Arbor Technologies release

Blue Arbor Technologies raised $10.5M in a Series A led by Ottobock, its strategic partner, announced October 28. The Michigan company is building RESTORE, a neuromuscular interface that reads the peripheral nervous system to drive a robotic prosthetic arm with independent control of the fingers, wrist and elbow. CEO Tod Borton runs the company out of Grass Lake.

RESTORE carries an FDA Breakthrough Device Designation and a slot in the agency's TAP pilot. It is investigational, with no clearance or approval. The round funds feasibility studies, an IDE application covering US clinical work on the external sensing unit, and the start of development on a fully implantable internal unit. Running the external and implantable programs in parallel on $10.5M is aggressive; most companies finish the external device first and raise again for the implant.

Questions & Answers

How much did Blue Arbor Technologies raise and who led the round?

Blue Arbor Technologies raised a $10.5 million Series A announced on October 28, 2026, led by Ottobock, which the company describes as its strategic partner.

What is the Blue Arbor RESTORE Neuromuscular Interface System?

RESTORE is Blue Arbor Technologies' investigational neuromuscular interface that connects a patient's peripheral nervous system to a robotic prosthetic limb, allowing independent control of the fingers, wrist and elbow. It holds FDA Breakthrough Device Designation and a place in the FDA's TAP pilot.

What will Blue Arbor Technologies do with the $10.5M Series A?

Blue Arbor Technologies will complete feasibility studies, file an FDA Investigational Device Exemption to support US clinical studies of the external sensing unit, and begin development of a fully implantable internal sensing unit.

← Back to Fundraising